Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

46.64
Delayed Data
As of Jan 16
 -0.26 / -0.55%
Today’s Change
29.39
Today|||52-Week Range
47.25
+10.23%
Year-to-Date
Teva's Trisenox Gets FDA Approval as First-Line Treatment
Jan 16 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Allergan Announces Job Cuts, Pfizer Inks Deals
Jan 05 / Zacks.com - Paid Partner Content
Allergan's (AGN) Sales Guidance for 2018 Lower Than Expected
Jan 09 / Zacks.com - Paid Partner Content
Allergan to Cut Jobs Amid Loss of Exclusivity for Key Drugs
Jan 04 / Zacks.com - Paid Partner Content
Momenta Reports Positive Top-Line Data on Antibody M281
Jan 09 / Zacks.com - Paid Partner Content
Momenta & Mylan to Initiate Trial on Biosimilar of Eylea
Jan 04 / Zacks.com - Paid Partner Content
Key Biosimilar Approvals in 2017: Progress Report
Jan 05 / Zacks.com - Paid Partner Content